The International Collaboration on Cosmetics Safety enters a new chapter with the appointment of its 2026 Board officers, reinforcing its global commitment to advancing animal-free approaches in cosmetics safety science at a time of rapid regulatory and scientific change.
The International Collaboration on Cosmetics Safety (ICCS) has announced its confirmed Board officers for 2026, following elections conducted during the organization’s December 2025 Board meeting, marking a notable achievement for the still young global initiative as it advances its role in promoting scientifically sound, human‑relevant alternatives to animal testing in cosmetics safety evaluation, with the newly appointed leadership illustrating both continuity and the increasing sophistication of ICCS as it builds on a year of meaningful advancements and prepares to broaden its influence across regulatory, scientific, and industry spheres worldwide.
ICCS operates at the intersection of science, policy, and collective engagement, bringing together a wide spectrum of stakeholders who pursue a common goal: promoting the global acceptance and implementation of animal-free safety science for cosmetics and their ingredients. The designation of the 2026 Board officers underscores the organization’s dedication to maintaining a strategic direction while adapting to an increasingly complex international landscape, where expectations related to ethical research, scientific rigor, and regulatory alignment continue to evolve.
Continued leadership stability and expansive global representation
The 2026 Board leadership brings together senior figures from across the cosmetics, consumer products, and regulatory advocacy sectors, reflecting the multi-stakeholder nature that has defined ICCS since its inception. Stéphane Dhalluin, Ph.D., DABT, Global Head of Human & Environmental Safety Evaluation at L’Oréal, has been re-elected as Chair of the Board of Directors. His reappointment signals confidence in a leadership approach that has emphasized scientific credibility, global cooperation, and constructive engagement with regulators.
Serving alongside him as Vice Chair is Darren Praznik, President and Chief Executive Officer of Cosmetics Alliance Canada, whose long-standing work in industry advocacy and regulatory engagement offers a valuable blend of regional insight and policy expertise. The role of Secretary will be held by Heike Scheffler, Ph.D., Safety Advocacy and Regulatory Toxicology Director for Global Product Stewardship in Beauty and Oral Care at Procter & Gamble, bringing extensive knowledge of regulatory toxicology and international product safety systems. Michael Southall, Ph.D., Senior Director and Head of Global Toxicology and Clinical Safety within Medical Clinical & Safety Sciences at Kenvue, has been elected Treasurer, contributing significant leadership experience in toxicology and organizational governance.
Together, the officers constitute a leadership team whose background extends across multinational corporations, industry groups, and regulatory science, thereby strengthening ICCS’ role as a neutral forum for collaboration rather than a promoter of any individual sector. This equilibrium remains essential to the organization’s credibility, especially as it aims to shape regulatory perspectives and foster alignment on animal-free safety approaches.
Driving progress in animal-free science through collective collaboration
At the heart of ICCS’ mission is the belief that animal-free approaches to safety assessment are not only ethically preferable but scientifically superior when properly developed and validated. Since its formation in early 2023, ICCS has worked to demonstrate that non-animal methods can provide reliable, relevant information for protecting both human health and the environment. The confirmation of the 2026 Board officers comes at a moment when this message is gaining traction, supported by tangible outputs and growing engagement from regulators around the world.
During 2025, ICCS delivered a series of initiatives that strengthened its scientific foundation and expanded its influence. Among these was the release of a Best Practice Guidance document, designed to provide clarity and consistency in the application of animal-free safety assessment approaches. This guidance aimed to bridge gaps between scientific innovation and regulatory expectations, offering a practical framework that stakeholders could reference when developing or evaluating non-animal data.
In parallel, ICCS supported the development of new methodologies aligned with next generation risk assessment (NGRA), an evolving paradigm that integrates advanced in vitro, in silico, and exposure-based approaches. These methodologies are increasingly viewed as essential to modern toxicology, offering the potential for more human-relevant insights while reducing reliance on animal testing. ICCS’ involvement in this space reflects its commitment to advancing not only ethical outcomes but also scientific excellence.
ICCS has also placed strong emphasis on maintaining ongoing dialogue. Throughout 2025, the organization engaged in wide-ranging interactions with regulators, scientists, and policymakers across multiple regions, guiding discussions on how animal‑free data might be assessed and integrated into existing regulatory frameworks. These exchanges have been essential in building shared understanding and trust, particularly in areas where the incorporation of non‑animal methodologies is still progressing.
A pivotal milestone reshaping the oversight of cosmetics safety
The installation of the 2026 Board officers takes place during a phase marked by notable transformations in global cosmetics regulations, as many markets reassess long‑standing testing standards in response to public expectations, scientific advancements, and new international policy trends, and within this shifting environment, organizations like ICCS remain vital in aligning innovation with regulatory requirements to ensure that progress continues to be both reliable and sustainable.
ICCS leadership has consistently emphasized that progress in animal-free safety science cannot arise from isolated efforts; instead, it requires coordinated action among industry, academia, regulators, and civil society. This perspective is reflected in the composition of the Board, which brings together leaders who understand the technical, regulatory, and organizational dimensions necessary to foster significant transformation.
Statements from ICCS leadership following the elections highlighted both confidence and realism. While there is recognition of the momentum generated in recent years, there is also acknowledgment that significant work remains. Achieving widespread regulatory acceptance of animal-free approaches will require continued investment in research, transparent data sharing, and ongoing engagement with authorities to address legitimate questions around reliability, applicability, and protection of public health.
The re-elected Chair emphasized the importance of leveraging ICCS’ global, multi-stakeholder model to close the gap between innovation and regulation. This approach aims to ensure that advances in animal-free science are not confined to research settings but translated into practical tools that regulators can trust and apply consistently.
Strengthening the foundation for enduring influence
As ICCS looks ahead to 2026 and beyond, the organization is focused on consolidating its achievements while expanding its reach. The newly confirmed Board leadership is expected to play a central role in shaping priorities that balance scientific ambition with practical implementation. This includes identifying areas where additional guidance or consensus-building is needed, supporting the validation and communication of new methodologies, and fostering international alignment to reduce fragmentation in regulatory requirements.
Education remains a core element of ICCS’ strategy, as the organization works to provide accessible, science‑based resources and forums for discussion that illuminate the foundations of animal‑free safety science and enable well‑informed decision‑making. This mission becomes particularly crucial in a field where misconceptions or uneven expertise may slow progress, even when the underlying science is strong.
The organization’s structure, which unites top cosmetics and ingredient manufacturers with trade associations, research groups, and animal protection organizations, places it in a distinctive position to address these challenges. This diverse range of perspectives ensures discussions remain balanced, comprehensive, and focused on shared goals rather than narrow priorities.
Based in New York, ICCS remains active as a global initiative that underscores the inherently international landscape of cosmetics research and regulation. As products and ingredients frequently cross national borders, aligning standards and encouraging mutual acceptance of safety practices become ever more crucial. By working collaboratively, ICCS aims to support this alignment, minimize redundant efforts, and strengthen confidence in animal-free science around the world.
By confirming its 2026 Board officers, ICCS underscores both consistency and a clear drive toward progress, with a leadership group that extends the momentum of a year defined by tangible accomplishments while offering the insight and expertise required to steer the coming stage of transformation; as scientific innovation quickens and regulatory expectations shift, the organization’s function as a unifying force and driver of animal-free cosmetics safety science is poised to gain even greater significance.
Ultimately, the significance of the 2026 Board elections arises not only from who is chosen but also from the message their leadership sends: a sustained commitment to collaboration, scientific rigor, and the careful advancement of alternatives to animal testing. For ICCS and its stakeholders, the coming years offer an opportunity to convert vision into lasting outcomes, guiding the future of cosmetics safety in a way that unites ethics, science, and global public trust.
